: To clarify the relationship between fluorescein angiography (FA) leakage after infliximab therapy and ocular attack relapse in patients with ocular Behçet's disease (BD). : Patients with ocular BD were divided into two groups based on the presence (Group 1) or absence (Group 2) of ocular attacks after IFX therapy. FA leakage was evaluated by FA score in each of the optic discs, macula, large retinal vessels, and capillary vessels. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the relationship between FA score after IFX therapy and ocular attack relapse. : The areas under the curves obtained from the ROC curve of optic disc score and capillary vessels score after IFX therapy were 0.867 (95% confidence interval [CI]: 0.788-0.946) and 0.788 (95% CI: 0.649-0.927), respectively. : FA leakage in the optic disc and capillary vessels after IFX therapy was strongly related to ocular attack relapse.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2019.1641611 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of Crohn's Disease With Infliximab and Subsequent Development of Takayasu's Arteritis.
Gastroenterology Res
December 2024
Department of Gastroenterology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
A 23-year-old man was diagnosed with Crohn's disease (CD) of the large intestine after colonoscopy revealed longitudinal ulcers, and pathology revealed non-caseating epithelioid cell granulomas and anal fistulas. The CD relapsed, and therefore prednisolone (PSL) and infliximab (IFX) treatment was initiated. The PSL was gradually tapered.
View Article and Find Full Text PDFIntroduction: Biologic therapies treat patients with moderate to severe inflammatory bowel disease (IBD). This study aims to investigate the demographics of biologic therapy use and its association with patient characteristics, a topic that has not yet been thoroughly assessed in our region.
Methods: Electronic health record data from June 1, 2021, to May 31, 2023, were collected at a tertiary care IBD center in Kuwait.
Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease.
Sci Rep
January 2025
Department of Paediatric Surgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
The aim was to explore factors associated with intestinal tissue levels of anti-TNF alpha (anti-TNF), anti-TNF antibodies, and cytokines in pediatric patients with Crohn Disease (CD). In a prospective exploratory study of CD patients undergoing ileocecal resection or colonoscopy between 6/2020 and 1/2023, we analysed tissue levels of anti-TNF, anti-TNF antibodies, and cytokines (TNF-α, IL-17, IL-1β, IFN-γ) from intestinal biopsies. Mixed-effects regression models, adjusted for potential confounders, were used.
View Article and Find Full Text PDFComparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis.
Saudi J Gastroenterol
January 2025
Department of Gastroenterology, Ankara City Hospital, Ankara, Turkey.
Background: To compare the long-term safety and efficacy of Adalimumab (ADA) and Infliximab (IFX) agents in biologic-naive patients with Ulcerative colitis (UC).
Methods: The key focus was on specific outcomes such as the requirement of hospitalization due to UC, colectomy, steroid administration, and severe infections that led to the discontinuation of therapy.
Results: Anti-TNF treatment was initiated in 208 of the 475 patients with ulcerative colitis.
The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis.
Turk J Med Sci
December 2024
Division of Clinical Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkiye.
Article Synopsis
- The study aimed to explore the connection between serum antidrug antibodies (ADAbs), hypersensitivity reactions, and local injection site reactions in patients with ankylosing spondylitis and rheumatoid arthritis who were on anti-TNF treatments.
- Sixty-nine patients with ankylosing spondylitis and 46 with rheumatoid arthritis were evaluated, measuring their drug levels, disease activity scores, and conducting skin tests to assess hypersensitivity.
- Results indicated a significant link between hypersensitivity reactions (both immediate and local) and the intradermal tests in patients taking anti-TNF drugs, particularly with adalimumab and etanercept.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!